Media Contact Information:
Pure Communications, Inc.
Igenica Biotherapeutics to Present at the 21st Annual BioCentury Future Leaders In The Biotech Industry
BURLINGAME, Calif. – March 25, 2014 – Igenica Biotherapeutics, a company focused on the discovery and development of innovative antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer, announced today that Mary Haak-Frendscho, Ph.D., chief executive officer, will present a company overview at the 21st Annual BioCentury Future Leaders In The Biotech Industry conference.
The presentation will take place at the Millennium Broadway Hotel in New York City on Friday, March 28, 2014 at 11:30 a.m. in Presentation Room 302/303.
About Igenica Biotherapeutics
Igenica Biotherapeutics is focused on the discovery and development of antibodies and antibody-drug conjugates (ADCs) for the treatment of cancer. Igenica is the only biotherapeutic company that fully powers the ADC development spectrum from a patient-based approach to target and functional antibody discovery to the generation and manufacturing of homogeneous ADCs. Igenica’s integrated discovery engine has generated a robust pipeline of site-specific ADC candidates and functional antibodies to address critical needs of cancer patients. Led by a proven team of leaders with expertise in the development of therapeutic antibodies and ADCs, Igenica is funded by a premier group of life science investors including The Column Group, OrbiMed, 5AM Ventures and Third Rock Ventures. For more information, please visit www.igenica.com.
Pure Communications Inc.